September 25, 2012
Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.
December 5, 2013
…of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.
October 4, 2016
Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize certain cancer cells to radiation therapy that may improve tumor control and reduce treatment-related side effects.
November 27, 2017
A team of University of California San Diego School of Medicine and Moores Cancer Center researchers studying new drugs designed to break resistance to cancer immunotherapy has been awarded a V Foundation for Cancer Research translational grant of $600,000 over three years.
July 21, 2016
…specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moores Cancer Center looked for combinations of mutated genes and drugs that together kill cancer cells. The study, published July 21 in Molecular Cell, uncovered 172 new combinations that could form the basis for…
May 6, 2024
Researchers from University of California San Diego have developed a new AI tool to that generate new drug candidates for cancer, which could help streamline the typically laborious drug discovery process.
March 18, 2015
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well-known “resistance” mutations in the gene called epidermal growth factor receptor (EGFR).
November 16, 2011
Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.
November 9, 2015
In an effort to advance research on one of the deadliest forms of cancer, University of California, San Diego School of Medicine researchers Andrew Lowy, MD, and Tannishtha Reya, PhD, have been recruited for their expertise in preclinical modeling, clinical trials and stem cell biology to join a “dream team”…
August 25, 2014
…of a deadly brain cancer – are resistant to drug therapy. The answer lies not in the DNA sequence of the tumor, but in its epigenetic signature. These findings have been published online as a priority report in the journal Oncotarget.
